ClinicalTrials.gg
RecruitingNCT07096687TTM-STROKEUpdated Sep 17, 2025

Targeted Temperature Management in Acute Ischemic Stroke

An interventional study of Targeted Temperature Management with CB240_Aurora and Standard of care Temperature treatment in Ischemic Stroke, sponsored by Azienda Usl di Bologna. Recruiting at 1 site in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-09-17.

Sponsored by Azienda Usl di Bologna · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Sep 2025; still recruiting 1 year 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
22
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 81 studies in Ischemic Stroke with a site in Italy — 23 open to participants now, 29 under way, 2 of them phase 3. Ischemic Stroke · Italy.

Planned enrollment
43rd of 50
22 · median 227
Started
2025
with 10 others
No phase
31 of 81
9 open now
Primary completion
2026-09
later than 8 of 28 live
Registered
75th of 81
by date
Lead sponsor
4 of 81
Azienda Usl di Bologna

Among the 81 studies in Ischemic Stroke with a site in Italy, this one is the 43rd largest by planned enrollment of the 50 interventional ones that give a count, is one of 11 that started in 2025, is one of 31 with no phase, reaches primary completion later than 8 of the 28 other live ones, and was the 75th registered.

Ischemic Stroke

2,629 studies on the registry are indexed under Ischemic Stroke; 983 are open to participants now.

Browse Ischemic Stroke studies →

Open to participants now

23 of the 81 studies in Ischemic Stroke with a site in Italy are open now. Recruiting first, the newest first:

17 more — sign in →

All 23 open studies →

A study can be open while its sites in Italy have not opened yet or have stopped. Only those recruiting at a site in Italy →

Who these studies take

Of the 668 Ischemic Stroke studies recruiting now, 403 (60%) set no upper age limit and 62 (9%) stop at 75 or younger; 27 take children under 18; 41 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 81 studies in Ischemic Stroke with a site in Italy, or all of them as a file.
02

Study summary

The goal of this interventional trial is to evaluate whether the CB240_Aurora medical device is effective for targeted temperature management in adult patients with acute ischemic stroke. The main questions it aims to answer are: Is the CB240_Aurora effective in maintaining normothermia in patients with acute ischemic stroke? Does the medical device improve clinical and radiological outcomes? Is the medical device well tolerated by patients? Researchers will compare an interventional arm, in which the CB240_Aurora measures and treats body temperature to maintain normothermia, with a control arm, in which the CB240_Aurora only measures but does not treat body temperature. Participants will wear the medical device for 72 consecutive hours in the Stroke Unit. Outcome assessments will be performed at 72 hours, 7 days, and 3 months.

Read the detailed description

Neuroprotection is a potential therapeutic strategy to complement reperfusion and prevent the progression of cerebral ischemia in patients with acute ischemic stroke. One of the most promising approaches is Targeted Temperature Management (TTM), which involves controlling body temperature to prevent fever, maintain normothermia, or induce hypothermia in order to reduce brain injury and improve clinical outcomes. While hypothermia has demonstrated clinical benefits in patients with cardiac arrest and hypoxic- schemic encephalopathy, no significant evidence currently supports its efficacy in acute stroke. Maintaining normothermia through TTM may offer similar neuroprotective benefits with fewer complications. Current guidelines for patients with intracerebral hemorrhage, subarachnoid hemorrhage, and ischemic stroke recommend maintaining body temperature between 36°C and 37.5°C, ideally using automated control systems.

In this context, Neuron Guard has developed the CB240_Aurora device, which targets cerebral temperature through the vascular anatomy of the neck to enhance heat exchange. This system has shown potential in stabilizing brain temperature while maintaining systemic normothermia and reducing systemic side effects. Its use could be extended beyond intensive care settings to broader patient populations, both for managing fever episodes and for enhancing neuroprotection.

The experimental treatment with the CB240_Aurora device is designed as a complementary approach to standard therapies, aiming to improve their effectiveness. The device will continuously monitor body temperature and deliver treatment to maintain normothermia, defined as a temperature ≥36°C and \<37°C at the time of study inclusion.

In the control group, patients will receive care according to the latest ischemic stroke treatment guidelines, including standard temperature management. In this group, the CB240_Aurora device will be used exclusively for temperature monitoring without providing active treatment.

03

Conditions studied

  • Ischemic Stroke

Browse trials for

Keywords

  • ischemic stroke
  • neuroprotection
  • targeted temperature management
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age >18 years;
  • Both sexes;
  • Diagnosis of acute ischemic stroke confirmed by clinical evaluation by a neurologist and neuroimaging (CT or brain MRI);
  • Acute ischemic stroke with symptom onset within 48 hours;
  • Anterior circulation stroke with evidence on neuroimaging (CT angiography) of occlusion of the middle cerebral artery in segments M1, M2, or M3;
  • NIHSS score between 6 and 25;
  • First clinical stroke;
  • Axillary temperature ≥36°C and \<37°C;
  • obtained for study participation.

Exclusion criteria

Exclusion Criteria:

  • Stroke involving multiple vascular territories;
  • Presence of intracerebral hemorrhage;
  • Pregnancy;
  • Moderate-to-severe or severe pre-stroke disability defined as mRS >3;
  • Presence of a cardiac pacemaker or any other conditions contraindicating brain MRI.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
22 participants (estimated)

Study arms

  • Experimental
    Intervention Arm

    Patients will receive targeted temperature management to maintain normothermia using the CB240\_Aurora device.

    Device: Targeted Temperature Management with CB240_Aurora · Device: Standard of care Temperature treatment

  • Sham comparator
    Control Arm

    CB240\_Aurora device used exclusively in temperature monitoring and control mode according to clinical standards

    Device: Standard of care Temperature treatment

Interventions

  • DeviceTargeted Temperature Management with CB240_Aurora

    The proposed experimental treatment with the CB240\_Aurora device will serve as a complementary approach to standard therapies, aiming to enhance their effectiveness. The device will continuously monitor body temperature and deliver treatment to maintain normothermia, defined as a temperature ≥36°C and \<37°C at the time of study inclusion.

  • DeviceStandard of care Temperature treatment

    In the control group, patients will receive treatment according to the latest guidelines for the management of ischemic stroke, including standard body temperature management. The CB240\_Aurora device will be used exclusively in monitoring mode, without delivering any active treatment, and will be maintained for 72 consecutive hours from the time of enrollment

06

What researchers measure

Primary outcomes

  1. Duration of normothermia maintenance during the first 72 hours

    Measure the duration (in hours) of maintained normothermia (between \>36°C and \<37°C) through axillary temperature monitoring during the first 72 hours.

    Time frame: T0 (0 hour)T1; ( 72 hours)

Secondary outcomes

  1. Modified Rankin Scale (mRS)

    Functional outcome at 3 months, defined as the Modified Rankin Scale (mRS) score ranging from 0 to 6, with higher scores indicating worse outcomes

    Time frame: T2 (day 7); T3 (day 90)

  2. National Institutes of Health Stroke Scale (NIHSS)

    Clinical outcome at 7 days, defined as the National Institutes of Health Stroke Scale (NIHSS) score ranging from 0 to 42, with higher scores indicating worse outcomes

    Time frame: T2 (day 7); T3 (day 90)

  3. Change in the volume of the ischemic lesion measured by MRI

    Ischemic lesion volume will be evaluated by MRI at day 7 from randomization (T0)

    Time frame: T2 (day 7)

  4. hemorrhagic transformation of the ischemic lesion at MRI

    hemorrhagic transformation of the ischemic lesion at MRI

    Time frame: T2 (day 7)

  5. Incidence of adverse events (AEs) and severe AEs (SAEs) that are related to treatment.

    Safety will be assessed by measuring the incidence of AEs and SAEs throughout the stimulation period and during the 3-month follow-up

    Time frame: T0 (day 0); T1 (day 3); T2 (day 7); T3( day 90)

  6. Number of patients requiring to stop treatment sessions

    Time frame: from T0 (day 0); T3 (day 90)

  7. Qualitative assessment of device tollerability (QADT)

    An ad hoc questionnaire to assess the tolerability of the device (e.g., nausea, headache, palpitations, anxiety, sweating) will be administered daily during the entire hospital stay and, after discharge, at each outpatient follow-up visit. Responses will be categorized as: Response No (Better Outcome) and Response Yes (Worse Outcome).

    Time frame: T2 (day 7); T3 (day 90)

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • Lavinio A, Beqiri E, Kataria K. A Novel Technology for Targeted Brain Temperature Management. Neurocrit Care. 2024 Apr;40(2):785-790. doi: 10.1007/s12028-023-01800-7. Epub 2023 Jul 27. No abstract available. PubMed 37498461 ↗
  • Lavinio A, Andrzejowski J, Antonopoulou I, Coles J, Geoghegan P, Gibson K, Gudibande S, Lopez-Soto C, Mullhi R, Nair P, Pauliah VP, Quinn A, Rasulo F, Ratcliffe A, Reddy U, Rhodes J, Robba C, Wiles M, Williams A. Targeted temperature management in patients with intracerebral haemorrhage, subarachnoid haemorrhage, or acute ischaemic stroke: updated consensus guideline recommendations by the Neuroprotective Therapy Consensus Review (NTCR) group. Br J Anaesth. 2023 Aug;131(2):294-301. doi: 10.1016/j.bja.2023.04.030. Epub 2023 May 22. PubMed 37225535 ↗
  • Dankiewicz J, Cronberg T, Lilja G, Jakobsen JC, Levin H, Ullen S, Rylander C, Wise MP, Oddo M, Cariou A, Belohlavek J, Hovdenes J, Saxena M, Kirkegaard H, Young PJ, Pelosi P, Storm C, Taccone FS, Joannidis M, Callaway C, Eastwood GM, Morgan MPG, Nordberg P, Erlinge D, Nichol AD, Chew MS, Hollenberg J, Thomas M, Bewley J, Sweet K, Grejs AM, Christensen S, Haenggi M, Levis A, Lundin A, During J, Schmidbauer S, Keeble TR, Karamasis GV, Schrag C, Faessler E, Smid O, Otahal M, Maggiorini M, Wendel Garcia PD, Jaubert P, Cole JM, Solar M, Borgquist O, Leithner C, Abed-Maillard S, Navarra L, Annborn M, Unden J, Brunetti I, Awad A, McGuigan P, Bjorkholt Olsen R, Cassina T, Vignon P, Langeland H, Lange T, Friberg H, Nielsen N; TTM2 Trial Investigators. Hypothermia versus Normothermia after Out-of-Hospital Cardiac Arrest. N Engl J Med. 2021 Jun 17;384(24):2283-2294. doi: 10.1056/NEJMoa2100591. PubMed 34133859 ↗
  • Wang H, Olivero W, Lanzino G, Elkins W, Rose J, Honings D, Rodde M, Burnham J, Wang D. Rapid and selective cerebral hypothermia achieved using a cooling helmet. J Neurosurg. 2004 Feb;100(2):272-7. doi: 10.3171/jns.2004.100.2.0272. PubMed 15086235 ↗
  • Lyden P, Hemmen T, Grotta J, Rapp K, Ernstrom K, Rzesiewicz T, Parker S, Concha M, Hussain S, Agarwal S, Meyer B, Jurf J, Altafullah I, Raman R; Collaborators. Results of the ICTuS 2 Trial (Intravascular Cooling in the Treatment of Stroke 2). Stroke. 2016 Dec;47(12):2888-2895. doi: 10.1161/STROKEAHA.116.014200. Epub 2016 Nov 10. PubMed 27834742 ↗
  • Lyden PD, Allgren RL, Ng K, Akins P, Meyer B, Al-Sanani F, Lutsep H, Dobak J, Matsubara BS, Zivin J. Intravascular Cooling in the Treatment of Stroke (ICTuS): early clinical experience. J Stroke Cerebrovasc Dis. 2005 May-Jun;14(3):107-14. doi: 10.1016/j.jstrokecerebrovasdis.2005.01.001. PubMed 17904009 ↗
  • You JS, Kim JY, Yenari MA. Therapeutic hypothermia for stroke: Unique challenges at the bedside. Front Neurol. 2022 Oct 3;13:951586. doi: 10.3389/fneur.2022.951586. eCollection 2022. PubMed 36262833 ↗
  • Yenari MA, Han HS. Neuroprotective mechanisms of hypothermia in brain ischaemia. Nat Rev Neurosci. 2012 Feb 22;13(4):267-78. doi: 10.1038/nrn3174. PubMed 22353781 ↗
  • Edwards AD, Brocklehurst P, Gunn AJ, Halliday H, Juszczak E, Levene M, Strohm B, Thoresen M, Whitelaw A, Azzopardi D. Neurological outcomes at 18 months of age after moderate hypothermia for perinatal hypoxic ischaemic encephalopathy: synthesis and meta-analysis of trial data. BMJ. 2010 Feb 9;340:c363. doi: 10.1136/bmj.c363. PubMed 20144981 ↗
  • Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med. 2002 Feb 21;346(8):549-56. doi: 10.1056/NEJMoa012689. PubMed 11856793 ↗
  • Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, Smith K. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med. 2002 Feb 21;346(8):557-63. doi: 10.1056/NEJMoa003289. PubMed 11856794 ↗
  • Reith J, Jorgensen HS, Pedersen PM, Nakayama H, Raaschou HO, Jeppesen LL, Olsen TS. Body temperature in acute stroke: relation to stroke severity, infarct size, mortality, and outcome. Lancet. 1996 Feb 17;347(8999):422-5. doi: 10.1016/s0140-6736(96)90008-2. PubMed 8618482 ↗
  • Madden LK, Hill M, May TL, Human T, Guanci MM, Jacobi J, Moreda MV, Badjatia N. The Implementation of Targeted Temperature Management: An Evidence-Based Guideline from the Neurocritical Care Society. Neurocrit Care. 2017 Dec;27(3):468-487. doi: 10.1007/s12028-017-0469-5. PubMed 29038971 ↗
  • Donnan GA, Davis SM, Parsons MW, Ma H, Dewey HM, Howells DW. How to make better use of thrombolytic therapy in acute ischemic stroke. Nat Rev Neurol. 2011 Jun 14;7(7):400-9. doi: 10.1038/nrneurol.2011.89. PubMed 21670766 ↗
  • Savitz SI, Baron JC, Yenari MA, Sanossian N, Fisher M. Reconsidering Neuroprotection in the Reperfusion Era. Stroke. 2017 Dec;48(12):3413-3419. doi: 10.1161/STROKEAHA.117.017283. Epub 2017 Nov 16. No abstract available. PubMed 29146878 ↗
  • Rabinstein AA, Albers GW, Brinjikji W, Koch S. Factors that may contribute to poor outcome despite good reperfusion after acute endovascular stroke therapy. Int J Stroke. 2019 Jan;14(1):23-31. doi: 10.1177/1747493018799979. Epub 2018 Sep 6. PubMed 30188259 ↗
  • Vanacker P, Lambrou D, Eskandari A, Mosimann PJ, Maghraoui A, Michel P. Eligibility and Predictors for Acute Revascularization Procedures in a Stroke Center. Stroke. 2016 Jul;47(7):1844-9. doi: 10.1161/STROKEAHA.115.012577. Epub 2016 Jun 14. PubMed 27301945 ↗
  • Powers WJ. Acute Ischemic Stroke. N Engl J Med. 2020 Jul 16;383(3):252-260. doi: 10.1056/NEJMcp1917030. No abstract available. PubMed 32668115 ↗
  • Feigin VL, Forouzanfar MH, Krishnamurthi R, Mensah GA, Connor M, Bennett DA, Moran AE, Sacco RL, Anderson L, Truelsen T, O'Donnell M, Venketasubramanian N, Barker-Collo S, Lawes CM, Wang W, Shinohara Y, Witt E, Ezzati M, Naghavi M, Murray C; Global Burden of Diseases, Injuries, and Risk Factors Study 2010 (GBD 2010) and the GBD Stroke Experts Group. Global and regional burden of stroke during 1990-2010: findings from the Global Burden of Disease Study 2010. Lancet. 2014 Jan 18;383(9913):245-54. doi: 10.1016/s0140-6736(13)61953-4. PubMed 24449944 ↗

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Sep 2025 (actual). Primary completion is estimated for Sep 2026, 12 months after the start.

Of 576 non-industry interventional studies with no phase under Ischemic Stroke, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 48. This study's planned 12 months is below that.

Counting every sponsor, half of 656 studies reached it within 27 months; a quarter within 14 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 24, 2025
First posted
Jul 31, 2025
StartActual
Sep 11, 2025
Primary completionEst.
Sep 2026
CompletionEst.
Mar 31, 2027
Last update
Sep 17, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 17, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07096687
Lead sponsor
Azienda Usl di Bologna
Responsible party
Sponsor
First posted
Jul 31, 2025
Start date
Sep 11, 2025
Primary completion
Sep 2026 (estimated)
Completion
Mar 31, 2027 (estimated)
Last update
Sep 17, 2025

Study contacts

Andrea Zini
Contact
a.zini@ausl.bologna.it
+390516478810
Stefano Forlivesi
Contact
stefano.forlivesi@ausl.bologna.it
+390516478889
Andrea Zini
principal investigator · IRCCS Istituto delle Scienze Neurologiche di Bologna - AUSL of Bologna

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion